The Emerging Role of HER2 (ERBB2) Mutations in NSCLC - a podcast by ReachMD

CME credits: 0.25

Valid until: 19-04-2023

Claim your CME credit at https://reachmd.com/programs/cme/the-emerging-role-of-her2-erbb2-mutations-in-nsclc/13695/

HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD